Related Experiment Video

Updated: Feb 14, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.3K

Lipid-lowering medication reduces more target lesion than non-target lesion revascularizations: a cohort study

Elina Mantyniemi1, Mitja Laaperi2, Pasi Karjalainen1

  • 1Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Finland.

Annals of Medicine
|February 12, 2026
PubMed

Insights

Statin medication adherence significantly reduced target lesion (TL) revascularization after coronary stenting compared to new site target lesion (NTL). Diabetes and longer stent length increased TL risk, while statins offered protection.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Atherosclerosis Research

Background:

  • Long-term atherosclerosis progression post-stent implantation is not fully understood.
  • Identifying predictors for target lesion (TL) versus new site target lesion (NTL) coronary stenosis is crucial.

Purpose of the Study:

  • To determine factors predicting coronary artery disease progression as either TL or NTL stenosis.
  • To evaluate the impact of medication adherence and patient characteristics on lesion development post-stenting.

Main Methods:

  • Prospective cohort registry of 1970 patients undergoing percutaneous coronary stenting.
  • Ten-year follow-up to categorize new ischemic lesions as TL or NTL.
  • Analysis of cardiovascular events, revascularization rates, and associated risk factors.

Main Results:

  • A total of 639 (32.4%) patients experienced cardiovascular events over a median 9.5-year follow-up.
  • Target lesion (TL) events occurred earlier than new site target lesion (NTL) events (1.2 vs. 4.3 years).
  • Good statin adherence (>80%) reduced TL revascularization odds (OR 0.45), while diabetes (OR 2.07) and increased stent length (OR 1.26) raised TL odds.

Conclusions:

  • Statin medication adherence is a key factor in preventing target lesion (TL) revascularization compared to new site target lesion (NTL).
  • Diabetes and longer stent length are associated with an increased risk of TL events.
  • Understanding these predictors can optimize long-term management strategies for patients with coronary stents.
Abstract

Keywords:
NSTEMIPCISTEMIUAPacute coronary syndromemyocardial infarctionnon-target lesionstatintarget lesion

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.8K
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Vapor Pressure Lowering03:28

Vapor Pressure Lowering

The equilibrium vapor pressure of a liquid is the pressure exerted by its gaseous phase when vaporization and condensation are occurring at equal rates:
31.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
3